Assembly Biosciences announced new preclinical and in vitro data for its therapeutic candidates ABI-6250 and ABI-4334 at the European Association for the Study of the Liver (EASL) Congress. The late-breaker poster for ABI-6250 highlighted its preclinical profile as a potential once-daily oral therapy for chronic HDV infection.
Results for ABI-6250 demonstrated specific inhibition of both HDV and hepatitis B virus at low nanomolar levels in cell culture, along with selective inhibition of the NTCP bile acid transporter. In vivo data showed ABI-6250 elevated total bile acids at doses that indicated selective NTCP target engagement.
For ABI-4334, in vitro studies showed durable reduction in HBV nucleic acids and antigens in human hepatocytes following a one-month course of treatment. These data provide further insights into the potential for next-generation capsid assembly modulators to impact markers of chronic HBV infection.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.